Cyclo Therapeutics

Cyclo Therapeutics is a US-based biotech leveraging cyclodextrin chemistry to create novel treatments for challenging diseases, with its most advanced candidate, Trappsol® Cyclo™, in clinical development for Niemann-Pick Disease Type C. The company is expanding its pipeline to include Alzheimer's disease, aiming to address pathological protein aggregation. Founded in 2000, it operates as a public entity, driving programs from clinical trials towards potential regulatory approval. Its strategy centers on harnessing its proprietary drug delivery platform to improve therapeutic outcomes in underserved patient populations.

Proprietary cyclodextrin-based chemistry platform for mobilizing accumulated lipids and proteins, used as both active drug and drug delivery vehicle.

In NPC, competition includes other small molecules and gene therapies in development. In Alzheimer's, the landscape is intensely competitive with numerous large pharma and biotech companies targeting amyloid, tau, and other pathways, requiring superior efficacy or differentiation.